Mr. Anderson brings over 30 years of senior executive leadership experience in the medical device industry. Mr. Anderson is the founder and Chairman of Revival Healthcare Capital, a sustainable, high impact investment firm that specializes in medical devices and diagnostics. He currently serves on the boards of Apollo Endosurgery (Nasdaq: APEN) and Cardiologs, a leading cardiovascular artificial intelligence company; on the Executive Advisory Board of LEK Consulting, a leading healthcare consulting firm; and as an Independent Director of ConvaTec Group Plc, a FTSE 250 company specializing in medical products and related technologies. Anderson previously served as Chairman of the Board and CEO of ConvaTec Group Plc, where in his one-year interim roles he created additional shareholder value through his “Pivot to Growth” strategy and new $150 million transformation plan. Prior to his time with Revival Healthcare Capital, Mr. Anderson served as the Managing Director of PTV Healthcare Capital. He also served as the Company Group Chairman of Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Anderson was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER®️ Sirolimus-eluting Coronary Stent. Anderson holds a B.B.A. in Marketing from Mississippi State University.
Mr. Chen is a Principal at Warburg Pincus and joined the firm in 2011. Prior to Warburg Pincus, he worked as an Associate at the Carlyle Group in the U.S. Buyout Fund, and as an Analyst at Citigroup. Mr. Chen is a member of the Board of Directors of Silk Road Medical as well as Accriva Diagnostics, ComplexCare Solutions, Singular Bio, and Vertice Pharma. He received a B.S. magna cum laude in Economics and Computer Science from Duke University and an M.B.A. from Harvard Business School.
Dr. Chou is a general partner at The Vertical Group, a healthcare focused venture capital firm. He co-founded Silk Road with Michi Garrison in 2007 and served as initial CEO. His career includes practicing as an interventional cardiologist and experience as a medical device industry executive. He previously had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of the vascular closure managing the FDA approval and global launch of the Perclose and Starclose products. Prior to joining Abbott, Dr. Chou was the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco where he remains Associate Professor of Medicine. Dr. Chou received an MD from Case Western Reserve University and a BS in Physics and Electrical Engineering from Carnegie Mellon University.
Mr. Lasersohn has thirty years of experience in health care venture capital investments. Prior to joining The Vertical Group’s predecessor, F. Eberstadt in 1981 as a member of its venture capital division, Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore. Mr. Lasersohn has served on the boards of over thirty medical companies and currently serves on the Boards of Directors of Anova, Masimo Corporation, Oncomed, and Silk Road Medical. He previously served on the boards of Bacchus Vascular, CardioThoracic Systems, Inc., Cardiovascular Imaging Systems, Inc., E.P. Technologies, Integrated Vascular Systems, Kyphon Inc, Metabolix and Proteolix . Mr. Lasersohn served on the Executive Committee of the Board of Directors of the National Venture Capital Association and is a past Chairman of the Medical Industry Group of the NVCA . He was the recipient of the NVCA’s Outstanding Service Award in 2008. In 2011, Mr. Lasersohn was appointed by the Office of the President to serve as an Entrepeneur in Residence at the FDA to develop an Innovation Pathway for medical devices. In 2012 he was appointed by the Secretary of HHS as a guest panel member of the Medicare Coverage and Advisory Committee (MEDCAC). He received a B.S. degree in Physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School.
Elizabeth H. Weatherman has served as a Director of Silk Road Medical since September 2011. Ms. Weatherman has held a position as Special Limited Partner of Warburg Pincus LLC, a global private equity firm focused on growth investing, since January 2016. Ms. Weatherman previously was a Managing Director of Warburg Pincus and a member of the firm’s Executive Management Group. She joined the firm Warburg Pincus in 1988 and primarily focused on the firm’s healthcare investment activities. Ms. Weatherman also serves on the board of directors of Nevro Corp., Wright Medical Group N.V. and Vapotherm, Inc. Ms. Weatherman received a B.A. summa cum laude from Mount Holyoke College and holds an M.B.A. from the Stanford Graduate School of Business.
Don Zurbay is the former vice president and CFO of St. Jude Medical, Inc., a Fortune 500 multi-national medical device company. During his tenure at St. Jude Medical, Don helped guide the company through significant growth and expansion, including nineteen acquisitions, and ultimately the transaction to sell St. Jude Medical to Abbott for $25 billion. Prior to St. Jude Medical, Inc., Don spent 10 years in public accounting at Deloitte and PricewaterhouseCoopers and three years at The Valspar Corporation. Don attended the University of Minnesota and earned a Bachelor of Science Degree in Business with an emphasis in accounting. Don is a member of the American Institute of Certified Accountants and the Minnesota Society of Certified Public Accountants. He also participated in the Advanced Management Program at Harvard Business School in 2011.